Of the 54,966,186 shares outstanding that were eligible to make an election, 52,154,714, or 94.9%, elected to receive the Stock Election Consideration, 249,408, or 0.4%, elected to receive the Cash Election Consideration, 110,448, or 0.2%, elected to receive the Standard Election Consideration, and the remaining 2,451,616, or 4.5%, did not make any election and thus received the Standard Election Consideration. In accordance with the terms of the merger, Auxilium shareholders had the opportunity to elect one of three options with respect to transaction consideration: (i) 0.4880 Endo shares per Auxilium share (the "Stock Election Consideration"), (ii) $33.25 in cash per Auxilium share (the "Cash Election Consideration") or (iii) a standard election of $16.625 in cash and 0.2440 Endo shares per Auxilium share (the "Standard Election Consideration"), subject to proration in the case of elections to receive the Cash Election Consideration or Stock Election Consideration. We believe that Endo is now even better positioned to drive growth across our product portfolio and to capitalize on additional future strategic M&A opportunities to create value for shareholders, customers and employees." We continue to expect the transaction to be immediately accretive for shareholders and meaningfully accretive each year moving forward. "We are excited to deliver on the promise of this combination by leveraging our resources to enhance the performance of XIAFLEX and optimize TESTOPEL and STENDRA. "This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality products to our already robust portfolio and expanding our development pipeline," said Rajiv De Silva, President and CEO of Endo. With the acquisition complete, Endo's portfolio has a broader offering of urology and orthopedic products, including XIAFLEX ®, TESTOPEL ® and STENDRA ®, which are natural complements to its men's health and pain products. The combined company will provide an expanded platform to accelerate the evolution and growth of Endo's U.S. The closing of the transaction follows the approval of the acquisition by Auxilium's shareholders on January 27, 2015, and the receipt of all required regulatory approvals. in a transaction valued at $2.6 billion when announced on October 9, 2014. 29, 2015 /PRNewswire/ - Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced it has completed the acquisition of Auxilium Pharmaceuticals, Inc.
0 kommentar(er)
